Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new
treatments and biomarkers in oncology. PDX models are used to address clinically relevant …

Importance A critical decision in the management of metastatic castration-resistant prostate
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a …

Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …

Several lines of compelling pre-clinical evidence identify chemotherapy as a potentially
double-edged sword: therapeutic efficacy on the primary tumor may in fact be …

Cancer is a leading cause of morbidity and mortality worldwide. Over the past decades, the
concept of precision cancer medicine has emerged as a novel approach in the field of …

Nowadays, it is impossible to imagine modern cancer treatment without targeted therapies,
such as mAbs, that bind to tumor-associated antigens. Subsequently, mAbs can use a wide …

In the last few decades, the epithelial cell adhesion molecule (EpCAM) has received
increased attention as the main membrane marker used in many enrichment technologies to …

Abstract Background Circulating tumor cells (CTCs) expressing AR-V7 protein localized to
the nucleus (nuclear-specific) identify metastatic castration-resistant prostate cancer …

Circulating rare cells in the blood are of great significance for both materials research and
clinical applications. For example, circulating tumor cells (CTCs) have been demonstrated …